Winthrop Advisory Group LLC Grows Stake in Eli Lilly and Company $LLY

Winthrop Advisory Group LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,706 shares of the company’s stock after buying an additional 21 shares during the quarter. Winthrop Advisory Group LLC’s holdings in Eli Lilly and Company were worth $1,330,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. PNC Financial Services Group Inc. boosted its holdings in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares during the last quarter. Vanguard Group Inc. raised its position in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after purchasing an additional 4,975,395 shares during the period. Wellington Management Group LLP increased its position in shares of Eli Lilly and Company by 0.6% during the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock worth $10,495,261,000 after acquiring an additional 81,587 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Eli Lilly and Company by 13.3% during the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock worth $4,808,443,000 after acquiring an additional 682,203 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Eli Lilly and Company during the first quarter worth about $4,613,912,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.1%

LLY stock opened at $844.30 on Wednesday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a 50-day moving average of $736.97 and a two-hundred day moving average of $766.03. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $937.00. The stock has a market capitalization of $799.09 billion, a price-to-earnings ratio of 55.18, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter last year, the company earned $3.92 earnings per share. The firm’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Insiders Place Their Bets

In other Eli Lilly and Company news, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the purchase, the director owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock valued at $2,894,841 over the last quarter. Company insiders own 0.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. Berenberg Bank reiterated a “hold” rating and set a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Guggenheim reduced their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a research report on Wednesday, August 13th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Finally, Cantor Fitzgerald cut their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $938.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.